Simulating a non-core asset divestiture — identifying carve-out candidates, separating shared infrastructure, and running a structured sale process
Every mature pharmaceutical portfolio accumulates assets that no longer fit the company it has become — legacy brands from an earlier strategic era, adjacent-indication programs picked up in an acquisition, or products sitting outside the therapeutic areas where the company now concentrates capital and talent. Before any divestiture can be planned, corporate development must first draw a defensible line between what stays and what goes.
Non-core exposure rarely arrives through a single bad decision — it accretes gradually. A company acquires a mid-size competitor primarily for one flagship asset and inherits three or four smaller marketed products in indications it never intended to compete in. A research program that started inside a core therapeutic area drifts, over a decade of indication expansion, into adjacent biology the company has no commercial infrastructure to support. A geography-specific brand keeps generating steady cash flow long after the company's strategic center of gravity has shifted elsewhere.
None of these assets are necessarily bad businesses. The problem is fit, not quality: each one consumes management attention, manufacturing capacity, regulatory headcount, and capital that could otherwise concentrate behind the handful of programs the company has decided will define its next decade.
A rigorous portfolio review scores every asset against a small set of weighted dimensions rather than relying on gut feel: therapeutic-area focus (does the asset sit inside or outside the two or three disease areas the company has chosen to lead in), growth potential (addressable market size, competitive intensity, remaining patent runway), resource intensity (capital draw, dedicated headcount, manufacturing footprint relative to revenue contribution), and platform synergy (shared mechanism of action, shared manufacturing lines, or shared commercial infrastructure with core products).
Each dimension is typically scored on a simple ordinal scale and combined into a single composite fit score, then plotted against financial performance to produce a two-axis portfolio map. The output sorts every asset into one of three buckets: clearly Core (strong fit, retain and invest), clearly Non-Core (weak fit, screen for divestiture), and a smaller "hold and fix" middle category that gets revisited at the next review cycle rather than acted on immediately.
Classification is deliberately not a simple revenue ranking. A modestly-sized product tightly woven into core manufacturing and commercial infrastructure often scores as Core despite unremarkable financials, while a larger-revenue asset with no strategic overlap can still be flagged Non-Core — fit, not size, drives the split.
The practical output of this stage is a visual portfolio map — strategic fit on one axis, financial contribution on the other — that gives the leadership team a shared picture of the entire asset base at a glance. Assets settle into the Core zone or the Non-Core zone based on their composite position, and that positioning becomes the starting input for every downstream decision: which assets get a divestiture screen, which get renewed investment, and which are simply too entangled with core operations to move regardless of their standalone attractiveness.
This map is refreshed on a regular cadence — typically annually, with ad hoc updates whenever the company undergoes a strategy reset, a major acquisition, or a therapeutic-area exit — because strategic fit is a moving target, not a one-time judgment.
Being classified Non-Core is necessary but not sufficient for a divestiture to make sense. A second filter — standalone commercial viability — determines which non-core assets can realistically be separated and sold, and which remain too entangled with the parent's operations to extract without destroying the value they currently generate.
A non-core asset becomes a genuine carve-out candidate only if it can plausibly stand on its own, or transfer cleanly into a buyer's operations. Corp-dev teams assess this along several practical dimensions: can the product be manufactured under a bounded contract rather than requiring indefinite access to the parent's production lines; does it carry distinct regulatory filings and marketing authorizations that can be transferred without unwinding a combined dossier; is there a separable body of intellectual property with clean title; and does the asset generate enough standalone revenue and margin to interest a buyer once shared-cost allocations are stripped out.
Assets that pass this filter get prioritized for active sale preparation. Assets that fail it are not necessarily kept forever — they may simply need a period of operational de-entanglement before they become sellable.
Even a non-core asset with attractive standalone economics can be deprioritized if it is too deeply woven into core operations to separate without disproportionate cost or disruption. Entanglement shows up as shared manufacturing lines that cannot be split without a capital-intensive tech transfer, combination-product regulatory filings that bundle the non-core asset with a core one, shared ERP and IT systems that would require a bespoke carve-out build, or a sales force that details the non-core product alongside flagship core brands using the same territory structure.
The visual shorthand corp-dev teams use is a set of connecting threads between each candidate and the core zone: thin threads indicate light, cleanly severable dependencies; thick threads indicate deep operational entanglement that will make separation slow, expensive, and risky to execute on an aggressive timeline.
Divesting an asset does not automatically shrink the cost base behind it — this is the stranded-cost problem. Shared manufacturing overhead, shared field-force costs, and shared back-office capacity that used to be allocated across a wider asset base remain fixed even after the divested asset's revenue leaves, unless the seller actively right-sizes that capacity in parallel with the sale.
With a shortlist established, candidates are typically ranked on a simple value-versus-complexity matrix: high standalone value and low entanglement complexity gets executed first, since it is the fastest path to proceeds and the clearest signal of strategic intent to the market. Higher-complexity candidates are sequenced later, often after a de-entanglement work stream — splitting a shared manufacturing line, migrating off a shared ERP instance — has reduced the separation burden enough to make a clean sale realistic within a reasonable timeline.
No carve-out asset can be unplugged from a parent company overnight. A Transition Services Agreement is the contractual bridge that keeps shared functions running for the divested business during a defined wind-down period after signing, giving the buyer continuity while the seller works toward a clean, complete exit.
Separation planning starts by inventorying every function the carve-out asset currently borrows from the parent. Manufacturing dependencies arise when the product is made on a shared line or at a shared site and cannot be immediately transferred to the buyer's own network or a contract manufacturer. IT and ERP dependencies arise when order-to-cash, inventory, and financial reporting all run inside the parent's enterprise systems. Regulatory dependencies arise when marketing authorizations are still held in the parent's name pending a formal transfer process that runs market by market. Sales-force dependencies arise when the same reps detail the divested product alongside retained core brands. Finance and back-office dependencies arise when a shared-services center handles payroll, accounts payable, and the monthly close for the whole portfolio, divested asset included.
Each dependency gets scoped, priced, and time-bound before the deal signs, because an unscoped TSA gap discovered after close is a far more expensive problem to solve under time pressure.
A well-drafted TSA specifies, function by function, exactly what service is provided, at what service level, for how long, and at what price — usually cost recovery plus a modest markup rather than a profit center for the seller. Crucially, it also specifies exit milestones: the buyer commits to a schedule for standing up its own manufacturing supply, its own IT stack, its own regulatory licenses, and its own commercial infrastructure, with the TSA stepping down function by function as each replacement capability comes online.
Governance matters as much as the legal terms: most carve-outs establish a joint TSA steering committee that meets on a fixed cadence to track exit progress, resolve service-level disputes, and approve any extension requests before they become a default assumption.
TSAs are structurally double-edged. The buyer needs the bridge to avoid an operational cliff on day one, but the seller wants the shortest possible bridge — every month a TSA function stays open is a month the seller keeps management distraction and stranded fixed costs that the divestiture was supposed to eliminate.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Manufacturing | 12–24 months | Product remains made on the seller's line under a bounded supply agreement | Exit via tech transfer to buyer facility or contract manufacturer |
| IT / ERP Systems | 6–12 months | Order-to-cash and reporting continue to run on the parent's enterprise systems | Exit via data carve-out plus buyer system stand-up |
| Regulatory Filings | 12–18 months | Marketing authorizations remain held by the seller pending transfer | Exit via sequential license transfer, market by market |
| Sales Force / Distribution | 6–9 months | Shared reps detail the divested product alongside retained brands | Exit via buyer field-force build-out or a contract sales bridge |
| Finance / Back Office | 3–6 months | A shared-services center handles payroll, AP/AR, and monthly close | Exit via standalone finance stack stand-up |
Once separation is scoped, the asset moves into a structured sale process designed to reach the widest credible buyer universe while carefully controlling how much sensitive information each party sees, and when — converting strategic intent into a competitive, price-discovering auction.
The process opens with a blind teaser — a one- or two-page anonymized summary of the asset's market position and financial profile, distributed broadly to gauge interest without disclosing the seller's or target's identity. Parties that express genuine interest sign a non-disclosure agreement and receive the Confidential Information Memorandum (CIM): a detailed document covering the asset's clinical and regulatory history, financial statements, manufacturing footprint, key contracts, and — critically for a carve-out — the proposed TSA scope and duration.
A process letter accompanies the CIM, setting a firm deadline and format for first-round bids and establishing the rules of engagement for the rest of the auction.
First-round indicative bids (often called Indications of Interest) are non-binding value ranges submitted based on the CIM alone, without full due diligence. The sell-side team screens these bids for credible valuation, financing capacity, and strategic fit, then invites a shortlist to management presentations and access to a virtual data room containing far deeper operational, legal, and financial detail.
Second-round final bids are binding and incorporate the results of full due diligence, a negotiated TSA term sheet, and a marked-up draft of the definitive purchase agreement — at this point the seller is evaluating not just headline price but every material deal term simultaneously.
Competitive tension among several credible final-round bidders is consistently the single largest lever on outcome — both on headline price and on softer terms like TSA flexibility, employee retention commitments, and indemnification caps — more impactful than almost any individual negotiating tactic used once a buyer has gone exclusive.
A seller weighing final bids looks well beyond the headline number: financing certainty (committed debt versus a financing-out contingency that could unwind the deal), antitrust and regulatory closing risk, the realism of the buyer's proposed closing timeline, how much TSA burden the buyer is asking the seller to carry, and how the buyer intends to treat transferring employees and sales reps. A lower headline bid with a clean, fast, low-risk path to close is frequently preferred over a higher bid carrying meaningful execution risk.
Signing a purchase agreement is not the finish line. The deal only creates value if the proceeds received, net of transaction costs, compare favorably to the realistic alternatives — and if the seller actually captures the freed-up capital and eliminated cost base rather than letting stranded overhead quietly erode the gain.
At close, the sale proceeds are benchmarked against two alternative outcomes the seller did not choose. The first is the standalone discounted-cash-flow value the asset would generate if the company simply kept it and ran it independently with dedicated capital allocation — an estimate of what the seller is walking away from as a going concern. The second is the opportunity cost of continued in-house investment: what the capital and management bandwidth currently tied up in the non-core asset could instead earn if redeployed against the core pipeline, discounted at the company's weighted average cost of capital or internal hurdle rate.
A divestiture is value-accretive precisely when sale proceeds, plus the value created by redeploying freed capital and management attention at the core hurdle rate, exceed both the standalone DCF and the opportunity-cost benchmark. When either alternative is close to or above the achieved sale price, the strategic case for the divestiture — beyond simple portfolio tidiness — becomes much harder to defend.
Closing hands off responsibility to a post-close governance team that tracks TSA exit milestones function by function against the schedule negotiated during separation planning. Slippage is common — a buyer's IT stand-up or regulatory transfer frequently runs behind plan — and every TSA extension request needs to be weighed against the ongoing cost and distraction it imposes on the seller.
In parallel, the seller must execute an explicit stranded-cost elimination plan: right-sizing manufacturing capacity, rationalizing IT licenses and shared-service headcount, and closing out facility space that is no longer needed once the divested asset's volume has left. Without this parallel work stream, the freed capacity simply sits idle on the seller's cost base.
Stranded costs are the single biggest way carve-out value evaporates after signing. If the seller does not actively eliminate the freed capacity in step with the TSA exit schedule, the net P&L impact of even a well-priced divestiture can turn negative despite a large upfront proceeds figure.
Proceeds are typically redeployed into core R&D investment, debt paydown, or shareholder returns — each a visible signal to investors that capital is being concentrated behind the company's stated strategic priorities rather than spread across a broad, unfocused asset base. Just as importantly, the management bandwidth and organizational focus freed up by shedding a non-core distraction feeds directly back into the next portfolio review cycle, sharpening the same core/non-core classification framework that started the process for the next asset in line.